Anupam Rasayan Q3/9M FY26 Results: Revenue Surge 84%/130%, PAT Up 71%/244%
Anupam Rasayan reported strong Q3 & 9M FY26 results. Consolidated revenue grew 84% YoY to ₹17,297 crore for 9M FY26 and 31% to ₹5,124 crore for Q3 FY26. PAT rose 71% to ₹1,662 crore for 9M FY26 and 12% to ₹606 crore for Q3 FY26. The company is acquiring US-based Jayhawk Fine Chemicals for ~$134M.
The substantial year-on-year growth in financial metrics and the significant strategic acquisition of a US-based company are expected to have a material impact on the company's future performance and market position.
The company reported significant year-on-year growth in revenue and profit for both consolidated and standalone figures for the quarter and nine months ended December 31, 2025. The strategic acquisition of Jayhawk Fine Chemicals further bolsters the positive outlook.
Anupam Rasayan India Limited announced its Unaudited Financial Results for the quarter and nine months ended December 31, 2025. For the nine months of FY26, the company reported consolidated revenue of ₹17,297 million (crore), a year-on-year growth of 84%, with EBITDA at ₹4,024 million (crore) and PAT at ₹1,662 million (crore), showing a 71% increase. Standalone revenue for the same period surged by 130% to ₹13,050 million (crore), with EBITDA at ₹3,217 million (crore) and PAT at ₹1,190 million (crore), up by 244% year-on-year.
In the third quarter of FY26, consolidated total revenue stood at ₹5,124 million (crore), an increase of 31% year-on-year, with EBITDA at ₹1,296 million (crore) and PAT at ₹606 million (crore), up 12%. Standalone quarterly revenue grew by 89% to ₹4,014 million (crore), with EBITDA at ₹1,056 million (crore) and PAT at ₹479 million (crore), marking a 150% year-on-year rise.
The company highlighted its strong performance driven by the ramp-up of recently commercialized molecules and improving traction in life sciences and performance materials. A significant strategic development was the signing of a definitive agreement to acquire Jayhawk Fine Chemicals Corporation in the United States for an enterprise value of approximately $134 million. This acquisition is expected to strengthen the company's global footprint and capabilities in advanced custom synthesis.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.